Secarna Pharmaceuticals, a biopharmaceutical company focusing on the discovery and development of antisense oligonucleotide (ASO) therapies to address challenging targets, has entered into a research agreement with a global pharmaceutical company to support research and discovery in the field of oncology. Under the agreement, the global pharmaceutical partner will leverage ASOs derived from Secarna’s LNAplus platform in support of anti-cancer therapies the partner is developing and commercializing. Additional details were not disclosed.
 
The LNAplus platform has been validated through numerous internal projects as well as multiple academic and industry collaborations such as with Firebrand Therapeutics, Lipigon Pharmaceuticals, and Met P Pharma.
 
“This first agreement with a large global pharmaceutical partner is a major milestone for Secarna and a crucial step in paving the path for a new generation of anti-cancer therapeutics,” said Jonas Renz, Managing Director and Co-founder of Secarna Pharmaceuticals. “The agreement is a further testament to our LNAplusTM approach of developing highly specific, safety-optimized and efficacious antisense oligonucleotide therapies for challenging targets.”